Inefficacy of Sildenafil treatment of idiopathic pulmonary hypertension.
DOI:
https://doi.org/10.52692/1857-0011.2021.3-71.49Keywords:
idiopathic pulmonary hypertension, sildenafil, pulmonary haemodynamicsAbstract
There were studied effects of phosphodiesterase inhibitor Sildenafil on clinical and functional status in young patientwith severe primary pulmonary hypertension. Sildenafil was applicated in dose of 50-100 mg daily for 12 weeks, clinicaland functional status were estimated initial and after every month of treatment. The retrospective analysis do not detectedany positive dynamics in all estimated parameters, this phenomena may be explained by individual patient refractivity onthis group of medicine.
References
Barst, R., Mcgoon, M., Mclauphlin, V., Tapson, V. et al. Beraprost therapy for pulmonary arterial hypertension.J. Am. Coll. Cardiol. 2003; 41 : 2119-2125.
Badesch, D., Abman, S., Simonneau, G., et al. Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evedence - Based Clinical Practice Guidelines. Chest. 2007; 131 : 1917-1928.
Haworth, SG. Primary pulmonary hypertension in childhood. Arch. Dis. Child. 1998; 79(5) : 452-455.
Higenbottam, T., Butt, A.Y., McMahon, A. Longterm intravenous prostoglandin (epoprostenol or ilioprost) for treatment of severe primary pulmonary hypertension. Heart. 1998; 80 : 151-155.
Gaine, S.P., Rubi,n L.J. Primary pulmonary hypertension. 1998; 352 : 719-725.
Mclaughlin, V., Presberg, K.W ., Doyle, R.L.,Abman, S.H.: Prognosis of pulmonary arterial hypertension . Chest. 2004; 126 : 78-92.
Mehta S. : Drug therapy for pulmonary hypertension : What’s on the menu today? Chest. 2004; 6 : 2045-2049.
Olschewski, H., Simmoneau, G., Gall, M. et al.: Inhaled iloprost in severe pulmonary hypertension. N. Engl.J. Med. 2002; 347 : 322-327.
Olschewski, H., Ghofrani, H, Seeger W. and the German PPH study group. Inhaled iloprost to treat severe pulmonary hypertension: An uncontrolled trial. Ann Intern Med. 2000; 132 : 435-443.
Rich, S. Executive Summary from the World Symposium on Primary Pulmonary Hypertension. 1998; WHO.
Rich, S., Kaufmann, S., Levy, P.S. The effect of high doses of caicium channel blockers in primary pulmonary hypertension. N. Engl. J. Med. 1992; 327 : 76-81.
Rubin, L.J. Primary pulmonary hypertension. N.Engl. J. Med. 1997; 336 : 111-117.
Sitbon, O., Humbert, J.L., Jagot, O., G. Simonneau.Inhaled nitric oxide as scrinning agent for safety identifying responders to oral calcium-channel blockersprimary pulmonary hypertension. Eur. Resp. J. 1998; 12 : 265-270.
Stoli, D., Rasch, H., Linka, A. et al. A randomised,controlled trial of bosentan in severe COPD. Eur. Respir.J. 2008, nr. 32, p. 619-628.
Sitbon, O., Galie, N. Treat-to-target strategies in pulmonary arterial hypertension : the importance of using multiple goals. Eur Respir Rev. 2010, nr. 19, p. 272-278.
Hoeper, M. et al. Treatment of pulmonary hypertension. The Lancet Respiratory Medicine. 2016, vol. 4, nr.4, p.323-336.
Lajole, A. et al. Combination therapy versus monotherapy in pulmonary arterial hypertension : a meta-analysis. The Lancet Respiratory Medicine. 2016, vol. 4, nr. 4,p. 291-305.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
